DANA vs Dauch
DAN and DCH side by side, both in motor vehicles and motor vehicle equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DAN and DCH compare
DANA is the larger company, worth 2.3 times as much as Dauch ($2.5B against $1.1B).
Dauch grew revenue faster over the last twelve months (65.0% versus 5.1% for DANA).
DANA keeps more of each dollar of sales as profit, with a net margin of 13.5% compared with −2.3% at Dauch.
DANA pays a dividend yielding 1.6%; Dauch does not pay one.
DANA scores higher on the StockData Score (15 against 7 for Dauch), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DAN | DCH |
|---|---|---|
| Size and price | ||
| Market cap | $2.5B | $1.1B |
| Share price | $23.19 | $4.63 |
| Change, 1 year | 8.4% | −25.0% |
| Change, 5 years | −1.8% | −50.9% |
| Beta (5Y) | 1.44 | 1.69 |
| Employees | 27K | 18K |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 3 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 2.4× | – |
| P/S | 0.3× | 0.1× (better) |
| P/B | 1.5× | 0.7× (better) |
| EV/EBITDA | 15.3× | 6.4× (better) |
| P/FCF | 28.7× | – |
| FCF yield | 3.5% (better) | −4.5% |
| Fair value | $19.85 | $6.11 |
| Margin of safety | −16.8% | 24.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.1% | 65.0% (better) |
| Revenue growth, 5Y average | 1.1% | 4.4% (better) |
| Net income growth (TTM) | 1804% (better) | −625% |
| EPS growth (TTM) | 2022% (better) | −491% |
| Profitability | ||
| Gross margin | 9.8% | 10.2% (better) |
| Operating margin | 3.2% (better) | 1.1% |
| Net margin | 13.5% (better) | −2.3% |
| FCF margin | 1.1% (better) | −0.51% |
| Return on equity | 74.5% (better) | −19.8% |
| Return on invested capital | 3.6% (better) | 2.0% |
| Financial health | ||
| Debt / equity | 0.92 (better) | 3.32 |
| Net debt / EBITDA | 5.04 (better) | 5.04 |
| Interest coverage | 2.2× (better) | 0.3× |
| Current ratio | 1.13 | 1.39 (better) |
| Altman Z-score | 2.13 (better) | 1.04 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.6% | – |
| Payout ratio | 4.9% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 32.0% | – |
| Buyback yield | 23.2% (better) | 0.82% |
| Shareholder yield | 24.8% (better) | 0.82% |
| Ownership | ||
| Held by institutions | 99.8% | 101% |
| Held by insiders | 1.6% | 4.4% |
| Insider net buying, 12 months | $0 | $182K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 8.3% |
Go deeper
- DAN stock overview
- DAN income statement
- DAN valuation and score
- DCH stock overview
- DCH income statement
- DCH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.